TESTING THE ACTIVITY OF THE SYNTHETIC COMPOUND DIPHENYLTIN (IV)N- BENZYL METHYL DITHIOCARBAMATE AGAINST BREAST CANCER MCF-7
Journal: International Journal of Pharmaceutical Sciences and Medicine (IJPSM) (Vol.7, No. 12)Publication Date: 2022-12-30
Authors : Mukhlis Sanuddin; Indri Meirista; Siska Emilia Nasril;
Page : 97-106
Keywords : Diphenyltin (IV) N-Benzylmethyldithiocarbamate; FTNMR; MCF-7 breast cancer;
Abstract
Breast cancer is the leading cause of death, especially for women in Indonesia. Compounds that are widely used for anticancer at present are organotin compounds, one of which is dithiocarbamate compounds, with several reports of antifungal, antibacterial, anticancer, anti-alkylation, and apoptosis-inducing activities of metal dithiocarbamate complexes and their mixed ligands. The purpose of this study was to determine the activity test of the synthetic compound Diphenyltin (IV) N-Benzylmethyldithiocarbamate Against Breast Cancer MCF-7 using the MTT Assay (Microculture Tetrazolium Technique) Assay and to determine the functional group and structure of the compound Dibutyltin (IV) N-Benzylmethylditiocarbamate, used Spectrophotometer test FTIR (Fourier Transformed Infrared) and FTNMR (Nuclear Magnetic Resonance). From this study, it was found that the synthetic compound Diphenyltin (IV) N-Benzylmethyldithiocarbamate is a very potent compound in inhibiting the development and growth of MCF-7 breast cancer cells, because the compound has an IC50 value that is smaller than 10 g/ml which is 69, 640ppm
Other Latest Articles
- AN OVERVIEW ON PHARMACEUTICAL EXCIPIENTS- THEIR ROLES AND APPLICATIONS
- Formulation and Evaluation of Controlled Release Tablet of Irbesartan
- Aspects of myocardial heterogeneity in assessment its remodeling
- Association between maximal aerobic capacity and heart rate variability
- Biomarkers in the diagnosis of neurodegenerative diseases
Last modified: 2022-12-24 17:19:44